No Data
Insider Purchase: Chief Executive Officer of $IRD (IRD) Buys 100,000 Shares
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design
Express News | Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of Apx3330 in Diabetic Retinopathy
Buy Rating Affirmed for Opus Genetics Amid Promising OPGx-LCA5 Treatment Results and Regulatory Progress
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)
Analysts' Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)
